Next-Generation Sequencing (NGS) MRD Testing Services

The contract seeks qualified providers to deliver Next-Generation Sequencing based Measurable Residual Disease testing services for hematologic malignancies using an FDA-cleared assay on blood, bone marrow, and FFPE tissue specimens. All testing must be performed in a laboratory that is both CLIA-certified and CAP-accredited to ensure regulatory compliance and analytical rigor. The services are intended to support clinical decision-making for veterans through highly sensitive, standardized MRD detection capable of identifying residual cancer cells at levels below conventional methods. The opportunity is structured as a subcontract under the Department of Veterans Affairs’ 260-NETWORK Contract Office 20 and is open for responses until July 10, 2026. The NAICS code 621511 categorizes this as a medical and diagnostic laboratory service. There is no set-aside designation specified, and the place of performance and point of contact details are not provided. Interested parties must submit proposals through the official SAM.gov portal before the deadline to be considered for award.